Board of directors

  • Christopher Molineaux

    Chairman

    Christopher Molineaux has served as Chairman of Aclaris’ board of directors since June 2019 and as a member of Aclaris’ board of directors since January 2014. Mr. Molineaux is President and CEO of Life Sciences Pennsylvania, the life sciences industry advocacy organization for the Commonwealth of Pennsylvania. Before joining Life Sciences Pennsylvania in 2009, Mr. Molineaux served as Worldwide Vice President of Pharmaceutical Communication and Public Affairs for Johnson & Johnson. Mr. Molineaux previously served as Vice President for Public Affairs at the Pharmaceutical Research and Manufacturers of America (PhRMA) and held positions at the Federal Department of Health & Human Services and the White House. He holds a Bachelor of Arts from the College of the Holy Cross.

  • Maxine Gowen

    Director

    Maxine Gowen founded Trevena, Inc. and served as its President and Chief Executive Officer from 2007 until October 2018. Prior to this, Dr. Gowen held a variety of leadership roles at GlaxoSmithKline (GSK) over a period of fifteen years. As Senior Vice President for the Center of Excellence for External Drug Discovery (CEEDD), she developed an innovative new approach to externalizing drug discovery in big pharma. Dr. Gowen was previously President and Managing Partner at SR One, the venture capital subsidiary of GSK, where she led its investments in, and served on the board of directors of, numerous companies. Until 2002, Dr. Gowen was Vice President, Drug Discovery, Musculoskeletal Diseases at GSK, responsible for drug discovery and early development for osteoporosis, arthritis and metastatic bone disease. Dr. Gowen held a tenured academic position in the School of Pharmacology, University of Bath, UK from 1989 to 1992. Dr. Gowen currently serves on the board of Akebia Therapeutics, Inc. since July 2014 and Idera Pharmaceuticals, Inc. since January 2016, both public biopharmaceutical companies, and on the board of the state biotechnology industry association, Life Sciences PA.  Dr. Gowen also served on the board of the national biotechnology industry association, BIO, from 2008 to 2018. Dr. Gowen graduated with a Bachelor of Science in biochemistry from the University of Bristol, UK, then received a Doctor of Philosophy in cell biology from the University of Sheffield, UK, and received a Master of Business Administration from the Wharton School of the University of Pennsylvania. Dr. Gowen was awarded a Doctor of Science by the University of Bath, UK.

  • William Humphries

    Director

    William D. Humphries has served as a member of Aclaris’ board of directors since September 2016. Mr. Humphries is President and Company Group Chairman of Ortho Dermatologics, a division of Bausch Health Companies, Inc.  Previously, he was President and CEO of Merz North America where he oversaw strategic direction and collaboration among three North American companies: Merz Pharmaceuticals LLC, Merz Aesthetics Inc., and Merz Pharma Canada Ltd. Before joining Merz, he served as President of Stiefel where he spearheaded two significant acquisitions and led the global integration of Stiefel into GlaxoSmithKline. Previously, Mr. Humphries held multiple senior executive roles within Allergan, Inc. He holds a Bachelor of Arts from Bucknell University and a Master of Business Administration from Pepperdine University.

  • Anand Mehra, M.D.

    Director

    Dr. Mehra has served as a member of Aclaris’ board of directors since September 2014. Dr. Mehra joined Sofinnova Investments, Inc., a biotech investment firm, in 2007 and currently serves as a General Partner. Prior to joining Sofinnova, Dr. Mehra worked in J.P. Morgan's private equity and venture capital group, and before that, Dr. Mehra was a consultant in McKinsey & Company's pharmaceutical practice. Dr. Mehra currently serves on the boards of directors of the publicly held companies Spark Therapeutics, Inc. and Merus N.V., as well as several private companies. Dr. Mehra received his Bachelor of Arts in political philosophy from the University of Virginia and a Doctor of Medicine from Columbia University's College of Physicians and Surgeons.

  • Andrew Powell, Esq.

    Director

    Andrew Powell is an independent consultant who has served as a member of Aclaris’ board of directors since January 2017. He currently serves as a member of the boards of the publicly held companies Motif Bio plc, Landec Corporation and Synthorx Inc., and of various privately held companies in the life sciences industry. Mr. Powell served as Senior Vice President, General Counsel and Corporate Secretary of Medivation, Inc. from 2015 through the company’s acquisition by Pfizer, Inc. in 2016. Prior to Medivation, Mr. Powell served as Executive Vice President, General Counsel and Corporate Secretary of InterMune, Inc. from 2013 to 2015, where he helped the company prepare for the U.S. approval and launch of Esbriet® (pirfenidone) as a treatment for idiopathic pulmonary fibrosis and played a leadership role in InterMune’s acquisition by Swiss drug maker Roche Holdings AG. Immediately prior to joining InterMune, he was Executive Vice President, General Counsel and Secretary at Cornerstone Therapeutics, Inc. through its successful sale to Chiesi Farmaceutici S.p.A. Prior to Cornerstone, Mr. Powell served as Senior Vice President and General Counsel at ImClone Systems, Inc. where he helped the company grow before playing a key role in a successful process that resulted in a sale to Eli Lilly and Company. Prior to ImClone Systems, he was part of the senior team that repositioned CollaGenex Pharmaceuticals, Inc. as a leader in dermatology. Early in his career, Mr. Powell held positions of increasing responsibility for nearly 15 years at the multinational health care company Baxter International, Inc., where he was instrumental in a series of transactions that established Baxter throughout Asia. Mr. Powell holds a Bachelor of Arts from the University of North Carolina at Chapel Hill and a Juris Doctorate from Stanford Law School.

  • Bryan Reasons

    Director

    Bryan Reasons has served as a member of Aclaris’ board of directors since April 2018 and serves as chairman of the audit committee. Mr. Reasons is the Executive Vice President and Chief Financial Officer of Mallinckrodt plc.  Prior to joining Mallinckrodt, Mr. Reasons served as the Chief Financial Officer of Amneal Pharmaceuticals, Inc. and prior to that as Senior Vice President, Finance and Chief Financial Officer of Impax Laboratories, Inc. until Amneal and Impax completed their business combination in 2018. Before joining Impax, he was Vice President, Finance of Cephalon, Inc. and of Teva Pharmaceutical Industries Ltd., following the acquisition of Cephalon by Teva. Mr. Reasons previously worked at E.I. Du Pont De Nemours and Company and at PricewaterhouseCoopers LLP. Since 2017, he has served on the board of directors and the audit committee of Recro Pharma, Inc. Mr. Reasons holds a Bachelor of Science in accounting from The Pennsylvania State University and a Master of Business Administration from Widener University. He is a certified public accountant in the Commonwealth of Pennsylvania.

  • Andrew Schiff, M.D.

    Director

    Dr. Schiff has served as a member of Aclaris’ board of directors since August 2017. Dr. Schiff joined Aisling Capital in 1999 and has served as a Managing Partner since 2006. Prior to joining Aisling Capital, Dr. Schiff practiced internal medicine for six years at The New York Presbyterian Hospital, where he maintains his position as a Clinical Assistant Professor of Medicine. Dr. Schiff served as a director of ZELTIQ Aesthetics, Inc., a publicly held medical technology company, from 2010 until its acquisition by Allergan in 2017. He also served on the board of directors of Agile Therapeutics, Inc., a publicly held women’s health specialty pharmaceutical company, from 2012 until 2016. Dr. Schiff currently serves as a director of a number of private companies. He is a longtime supporter and board member of the Visiting Nurse Service of New York, as well as other charitable organizations. Dr. Schiff received his Doctor of Medicine from Cornell University Medical College, his Master of Business Administration from Columbia University, and his Bachelor of Science, with honors in neuroscience, from Brown University.

  • Dr. Neal Walker

    Director, President and CEO

    Dr. Walker co-founded Aclaris and has served as President and CEO and a member of the board of directors since its inception in July 2012. He is a board-certified dermatologist and serial entrepreneur with over 20 years of experience in the life science industry. He began his pharmaceutical industry career at Johnson & Johnson. Dr. Walker co-founded NeXeption, LLC, a biopharmaceutical assets management company, in 2012. Prior to Aclaris, he co-founded and served as President and CEO and a member of the board of directors of Vicept Therapeutics, Inc., a dermatology-focused specialty pharmaceutical company, from 2009 until its acquisition by Allergan in 2011. Previously, Dr. Walker co-founded and led a number of life science companies, including Octagon Research Solutions, Inc., a software and services provider to biopharmaceutical companies (acquired by Accenture); Trigenesis Therapeutics, Inc., a specialty dermatology company, where he served as Chief Medical Officer (acquired by Dr. Reddy's Laboratories Ltd.); and Cutix Inc., a commercial dermatology company. He also co-founded and serves on the board of directors of the Dermatology Summit, Dermatology Innovation Forum, and Advancing Innovation in Dermatology. Dr. Walker is on the board of directors of Aldeyra Therapeutics, Inc., a publicly held biotechnology company, as well as Life Sciences Pennsylvania and several private companies. In 2016, Dr. Walker was awarded the Frank Baldino Bioscience CEO of the Year award and the Ernst & Young Entrepreneur of the Year Greater Philadelphia award. He is a Fellow of the American Academy of Dermatology. He received his Master of Business Administration from The Wharton School, University of Pennsylvania, his Doctor of Osteopathic Medicine from the Philadelphia College of Osteopathic Medicine, and a Bachelor of Arts in biology from Lehigh University.